gdc
PSSGuide_2020
Leukemia

Drugs for Leukemia

Here are the drugs and financial support services available to patients receiving treatment for Leukemia.
Acute Lymphoblastic Leukemia (ALL)

Arranon (nelarabine)

Drug company: Novartis
800-245-5356

Arranon is a nucleoside metabolic inhibitor used for the treatment of patients with T-cell acute lymphoblastic leukemia

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arranon:

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arranon for free until a prescription drug coverage becomes available to them.

Besponsa (inotuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Besponsa is a CD22-directed antibody-drug conjugate used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pfizer Oncology Together offers 1 financial assistance program for patients using Besponsa:

Pfizer Patient Assistance Program

This program provides Besponsa free, or at a savings, for eligible patients with no healthcare coverage, as well as for patients with government insurance (who have no available independent charitable foundation support).

Blincyto (blinatumomab)

Drug company: Amgen
888-427-7478

Blincyto is a bispecific CD19-directed CD3 T-cell engager used for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is in first or second remission, with minimal residual disease. Blincyto is also used for the treatment of patients with relapsed or refractory B-cell precursor ALL.

Amgen offers 3 financial assistance programs for patients using Blincyto:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Blincyto and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Assist 360

Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.

Amgen Safety Net Foundation

Qualifying, uninsured patients can receive Blincyto for free through Amgen’s nonprofit patient assistance program.

Erwinaze (asparaginase Erwinia chrysanthemi)

Drug company: Jazz Pharmaceuticals
888-837-4397

Erwinaze (asparaginase Erwinia chrysanthemi) is an asparagine-specific enzyme used for the treatment of patients with acute lymphoblastic leukemia.

Jazz Pharmaceuticals offers 1 financial assistance program for patients using Erwinaze:

JumpStart Patient Assistance Program

This program offers free Erwinaze for patients who meet the program’s requirements.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used, in combination with chemotherapy, for the treatment of adults with relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) and pediatric patients with Ph+ ALL.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Novartis Oncology Universal Co-Pay Program

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum annual benefit of $30,000.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until a ­prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda Oncology
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. Iclusig is also used for adults with Ph+ ALL and T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Takeda Oncology 1Point

Regardless of patients’ insurance status, this program identifies the financial assistance programs for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.

Takeda Oncology Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription, up to a maximum annual benefit of $25,000.

Kymriah (tisagenlecleucel)

Drug company: Novartis
844-459-6742

Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of young patients (up to age 25) with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Novartis’ Patient Assistance NOW offers 1 financial assistance program for patients using Kymriah:

Kymriah Cares

This program offers financial assistance to eligible patients to help them access Kymriah. Patients must meet program eligibility criteria to qualify for support. Patients should work with their treatment center to submit a Service Request Form for Patient Support to Kymriah Cares.

Marqibo (vincristine sulfate liposome)

Drug company: Acrotech Biopharma
888-537-8277

Marqibo is a vinca alkaloid used for the treatment of adult patients with Ph-negative acute lymphocytic leukemia (ALL).

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Marqibo:

STAR Co-Pay Assistance

Eligible, privately insured patients will pay $0 for the first injection of Marqibo and then $25 for each subsequent injection, with a maximum benefit of up to $10,000 annually.

STAR Patient Assistance Program

This program provides Marqibo free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Sprycel (dasatinib)

Drug company: Bristol-Myers Squibb
855-777-9235

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ acute lymphoblastic leukemia.

Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:

Sprycel Assist One Card

This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Sprycel may be eligible for help paying for their medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Acute Myeloid Leukemia (AML)

Daurismo (glasdegib) Tablets

Drug company: Pfizer
877-744-5675

Daurismo is a hedgehog pathway inhibitor used, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adults age 75 years or older, and in patients whose comorbidities prevent them from using intensive induction chemotherapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Daurismo:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible, privately insured patients with their monthly copay for Daurismo, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Daurismo for free or at a savings. Eligible patients who have government insurance may also receive Daurismo for free if they cannot find financial support from an independent charitable foundation.

Idamycin PFS (idarubicin hydrochloride)

Drug company: Pfizer
866-706-2400

Idamycin PFS is used, in combination with other approved antileukemic drugs, for the treatment of patients with acute myeloid leukemia.

Pfizer Oncology Together offers 1 financial assistance program for patients using Idamycin PFS:

Pfizer RxPathways

Patients who are prescribed a Pfizer specialty medicine, such as Idamycin PFS, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Idhifa (enasidenib) Tablets

Drug company: Celgene
800-931-8691

Idhifa is an IDH2 inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia with an IDH2 mutation.

Celgene offers 2 financial assistance programs for patients using Idhifa:

Celgene Commercial Co-pay Program

This program can reduce prescription copay to $25 and provides up to $10,000 per calendar year to cover copay or coinsurance costs for patients with private insurance.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication who meet certain financial criteria may receive Idhifa at no cost.

Mylotarg (gemtuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Mylotarg is a CD33-directed antibody-drug conjugate used for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, and relapsed or refractory CD33-positive AML in patients age 2 years or older.

Pfizer Oncology Together offers 1 financial assistance program for patients using Mylotarg:

Pfizer Patient Assistance Program

Eligible patients who do not have insurance and are unable to afford Mylotarg may receive their medicine free or at a savings through this program.

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for the treatment of adults with acute myeloid leukemia and FLT3 mutation.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-Pay Card Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $10 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until a prescription drug coverage becomes available to them.

Tibsovo (ivosidenib)

Drug company: Agios Pharmaceuticals
844-409-1141

Tibsovo is an IDH1 inhibitor used for the treatment of adults aged 75 or older or those who have comorbidities that preclude use of intensive induction chemotherapy who are newly diagnosed with acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test. Tibsovo is also used for the treatment of adults with relapsed or refractory AML associated with an IDH1 mutation.

myAgios Patient Support Services offers 4 financial assistance programs for patients using Tibsovo:

myAgios Commercial $25 Co-Pay Program

Eligible, privately insured patients will pay no more than $25 per Tibsovo prescription, with a maximum annual benefit of $25,000.

myAgios Patient Assistance Program

Patients who meet certain financial criteria and are uninsured or underinsured can receive Tibsovo free of charge through this program.

myAgios Quick Start Program

Patients who have private or government insurance that has been delayed by 5 or more business days may qualify to receive a free 14-day prescription of Tibsovo, up to 3 refills, for a total of 56 days of Tibsovo therapy.

myAgios Coverage Interruption Program

Eligible patients experiencing an interruption in their insurance coverage after having received at least 1 prescription through a commercial insurance will receive a free 30-day supply of Tibsovo, up to 2 refills, for a total of 90 days of Tibsovo.

Venclexta (venetoclax tablets)

Drug company: AbbVie/Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used, in combination with azacitidine, decitabine, or low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients age 75 years or older, or in patients with AML whose comorbidities prevent them from using intensive induction chemotherapy.

Genentech offers 2 financial assistance programs for patients using Venclexta:

Genentech BioOncology Co-pay Assistance Program

For privately insured patients, this program ensures a $5 copay for Venclexta, with up to a $25,000 benefit annually. This program has no income requirements.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Venclexta is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Vyxeos (daunorubicin + cytarabine) Liposome for Injection

Drug company: Jazz Pharmaceuticals
855-589-9367

Vyxeos is a liposomal combination of daunorubicin (an ­anthracycline topoisomerase inhibitor) and cytarabine (a nucleoside metabolic inhibitor) used for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Jazz Pharmaceuticals’ JazzCares program offers 2 financial assistance programs for patients who are prescribed Vyxeos:

JazzCares Out-of-Pocket Assistance

Patients with private insurance may qualify for assistance with out-of-pocket costs for Vyxeos.

JazzCares Patient Assistance Program

This program offers Vyxeos at no cost for patients who are uninsured or do not have coverage for Vyxeos. Patients must have a total household gross income of less than 400% of the federal poverty level. The benefit is subject to an annual maximum.

Xospata (gilteritinib)

Drug company: Astellas
844-632-9272

Xospata is a kinase inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia and FLT3 mutation, as detected by an FDA-approved test.

Xospata Support Solutions offers 3 financial assistance programs for patients using Xospata:

Xospata Copay Card Program

Eligible patients who have private insurance will pay as little as $0 per prescription of Xospata, with a maximum annual benefit of $25,000. This program has no income requirements.

Xospata Quick Start+ Program

This program provides a one-time, 7-day supply of Xospata at no cost to eligible patients who have private insurance and are experiencing an insurance-related delay in receiving their medication.

Astellas Patient Assistance Program

Through this program, patients who are uninsured or have insurance that excludes coverage for Xospata may qualify to receive their medication at no cost.

Zarxio (filgrastim-sndz)

Drug company: Sandoz
844-726-3691

Zarxio a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the time to neutrophil recovery and the duration of fever in patients with acute myeloid leukemia, after induction or consolidation chemotherapy treatment.

Sandoz One Source offers 1 financial assistance program for patients using Zarxio:

Sandoz One Source Commercial Co-Pay Program

Through this program, privately insured patients will pay $0 copay for the first dose of Zarxio and for subsequent doses, with a maximum benefit of $10,000 annually. There is no income eligibility requirement.

Chronic Lymphocytic Leukemia (CLL)

Arzerra (ofatumumab)

Drug company: Novartis
800-245-5356

Arzerra is a CD20-directed cytolytic monoclonal antibody used for the treatment of patients with chronic lymphocytic leukemia. In certain cases, Arzerra is used in combination with chlorambucil, or fludarabine and cyclophosphamide.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arzerra:

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arzerra for free until a prescription drug coverage becomes available to them.

Bendeka (bendamustine HCl) Injection

Drug company: Teva
888-587-3263

Bendeka is an alkylating drug used for the treatment of patients with chronic lymphocytic leukemia.

Teva offers 1 financial assistance program for patients using Bendeka:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,500 for 4 people, or $147,100 for 5 people.

Calquence (acalabrutinib) Capsules

Drug company: AstraZeneca
844-275-2360

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with chronic lymphocytic leukemia.

AstraZeneca 360 offers 2 financial assistance program for patients who are using Calquence:

CALQUENCE Co-pay Savings Program

Eligible patients who have private insurance will pay $0 per month and may have access to up to $26,000 annually to assist with the out-of-pocket prescription costs associated with Calquence.

AZ&Me Prescription Savings Program

This program offers free medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medication through participating healthcare facilities.

Copiktra (duvelisib)

Drug company: Verastem
833-570-2273

Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia, after at least 2 other therapies.

Verastem Cares offers 3 financial assistance programs for patients using Copiktra:

Verastem Cares Co-Pay Assistance

Patients who have private insurance may pay as little as $5 for their prescription of Copiktra, with a maximum annual benefit of $25,000. This program has no patient income requirement.

Verastem Cares Bridge Rx Program

This program provides a free 14-day supply of Copiktra to eligible patients who experience coverage delays or loss of insurance of longer than 5 days.

Verastem Cares Patient Assistance Program

Patients who are uninsured and have an annual income of $150,000 or less may qualify to receive Copiktra for free.

Gazyva (obinutuzumab)

Drug company: Genentech
866-422-2377

Gazyva is a CD20-directed cytolytic antibody used, in combination with chlorambucil, for the treatment of patients with untreated chronic lymphocytic leukemia (CLL). Gazyva is also used, in combination with Imbruvica or with Venclexta, for the first-line treatment of patients with CLL.

Genentech offers 2 financial assistance programs for patients using Gazyva:

Genentech BioOncology Co-pay Assistance Program

The program ensures a $5 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Gazyvafree of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a Bruton tyrosine kinase inhibitor used for the first-line treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion. Imbruvica is also used, in combination with Gazyva, for the first-line treatment of patients with CLL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and coinsurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Rituxan (rituximab)

Drug company: Genentech
866-422-2377

Rituxan is a CD20-directed cytolytic antibody used, in combination with fludarabine and cyclophosphamide, for the treatment of patients with chronic lymphocytic leukemia.
Rituxan is also used, in combination with Venclexta, for first-line treatment of CLL. is also used, in combination with Venclexta, for first-line treatment of CLL.

Genentech offers 2 financial assistance programs for patients using Rituxan:

Genentech BioOncology Co-pay Assistance Program

The program ensures a $5 copay for Rituxan for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Rituxan free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Rituxan is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Drug company: Genentech
866-422-2377

Rituxan Hycela is a combination of rituximab (a CD20-directed cytolytic antibody) and hyaluronidase human (an endoglycosidase) that is used, in combination with fludarabine and cyclophosphamide, for the treatment of untreated adults with chronic lymphocytic leukemia (CLL) and of previously treated CLL.

Genentech offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech BioOncology Assistance Program

PPrivately insured patients will pay only a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was refilled within 120 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For household with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Venclexta (venetoclax) Tablets

Drug company: Abbvie/Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used for the treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion, who have received at least 1 therapy. Venclexta is also used, in combination with with Gazyva or with rituximab, for the first-line treatment of patients with CLL.

Genentech offers 2 financial assistance programs for patients using Venclexta:

Genentech BioOncology Co-pay Assistance Program

The program ensures a $5 copay for Venclexta for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to un­­insured or underinsured patients whose annual household income is less than $150,000. Venclexta is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Zydelig (idelalisib) Tablets

Drug company: Gilead
844-622-2377

Zydelig is a kinase inhibitor used, in combination with Rituxan, for the treatment of patients with relapsed chronic lymphocytic leukemia.

Zydelig AccessConnect offers 3 financial assistance programs for patients using Zydelig:

Zydelig AccessConnect Copay Coupon Card

Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.

Zydelig QuickStart Program

The Zydelig QuickStart Program gives eligible patients who have an insurance coverage delay of more than 5 business days quick access to a free, one-time, 30-day supply of Zydelig.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Chronic Myeloid Leukemia (CML)

Bosulif (bosutinib)

Drug company: Pfizer
877-744-5675

Bosulif is a kinase inhibitor used for the treatment of adult patients with Ph+ chronic myeloid leukemia in the chronic, accelerated, or blast phase.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Bosulif:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Bosulif is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Bosulif for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Bosulif for free.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia in chronic, blast crisis, or accelerated phase, or in chronic phase after the failure of interferon-alpha therapy.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleeve::

Novartis Oncology Universal Co-Pay Program

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until a prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda Oncology
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML). Iclusig is also used for adults with chronic-, accelerated-, or blast-phase CML with T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Takeda Oncology 1Point

Regardless of patients’ insurance status, this program identifies the financial assistance programs for Iclusig for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.

Takeda Oncology Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription up to a maximum annual benefit of $25,000.

Sprycel (dasatinib)

Drug company: Bristol-Myers Squibb
855-777-9235

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia.

Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:

Sprycel Assist One Card

This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel with a reduced copay, in some cases $0 a month, up to a maximum annual benefit of $32,000. New cash-paying patients or new patients covered by a government-funded program are eligible for a free 30-day trial supply of Sprycel.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Sprycel, may be eligible for help paying for their prescription if they are receiving treatment as an outpatient and have an annual income up to 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Synribo (omacetaxine)

Drug company: Teva
888-587-3263

Synribo is used for the treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia.

Teva offers 1 financial assistance program for patients using Synribo:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Synribo for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,500 for 4 people, or $147,100 for 5 people.

Tasigna (nilotinib)

Drug company: Novartis
800-245-5356

Tasigna is a kinase inhibitor used for the treatment of patients older than 1 year with newly diagnosed chronic-­phase Ph+ chronic myeloid leukemia (CML), or for patients older than 1 year with chronic-phase Ph+ CML that is resistant to previous tyrosine kinase inhibitor therapy. Tasigna is also used for adults with chronic-phase or accelerated-phase Ph+ CML that is resistant to or who are intolerant of Gleevec.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Tasigna:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Tasigna. The program pays the remaining balance until an annual maximum of $15,000 is met.

Tasigna 3 Months Free Trial Voucher

Eligible new patients can receive a free 3-month trial supply of Tasigna capsules.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients must be without insurance, be US citizens, and provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Tasigna for free until a prescription drug coverage becomes available to them.

Hairy-Cell Leukemia (HCL)

Lumoxiti (moxetumomab pasudotox-tdfk)

Drug company: AstraZeneca
844-275-2360

Lumoxiti is a CD22-directed cytotoxin used for the treatment of adults with relapsed or refractory hairy-cell leukemia who have received at least 2 systemic therapies, including a purine nucleoside analog.

AstraZeneca Access 360 offers 1 financial assistance program for patients who have been prescribed Lumoxiti:

Access 360 Lumoxiti Patient Savings Program

Although the patient’s out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per infusion of Lumoxiti, with a maximum annual savings of $26,000. Eligible patients must have private health insurance that partially covers the costs of Lumoxiti.

Mast-Cell Leukemia

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used for the treatment of adults with mast-cell leukemia.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-Pay Card Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $25 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until a prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Leukemia

Acute Lymphoblastic Leukemia (ALL)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Besponsa (inotuzumab ozogamicin) for Injection
  • Drug company
  • Pfizer
  • Indication
  • Relapsed or refractory B-cell precursor ALL
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675


    Drug name (generic name)
  • Erwinaze (asparaginase Erwinia chrysanthemi)
  • Drug company
  • Jazz Pharmaceuticals
  • Indication
  • ALL
  • Patient support services
  • JumpStart Patient Assistance Program
    888-837-4397



    Drug name (generic name)
  • Kymriah (tisagenlecleucel)
  • Drug company
  • Novartis
  • Indication
  • B-cell precursor ALL in patients up to age 25
  • Patient support services
  • Kymriah Cares
    844-459-6742



Acute Myeloid Leukemia (AML)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Idamycin PFS (idarubicin hydrochloride)
  • Drug company
  • Pfizer
  • Indication
  • AML
  • Patient support services
  • Pfizer RxPathways
    866-706-2400


    Drug name (generic name)
  • Mylotarg (gemtuzumab ozogamicin) for Injection
  • Drug company
  • Pfizer
  • Indication
  • CD33-positive AML in adults

    Relapsed or refractory CD33-positive AML in patients age 2 or older
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675






    Drug name (generic name)
  • Zarxio (filgrastim-sndz)
  • Drug company
  • Sandoz
  • Indication
  • Treatment of AML
  • Patient support services
  • Sandoz One Source Co-Pay Program
    844-726-3691

Chronic Lymphocytic Leukemia (CLL)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Arzerra (ofatumumab)
  • Drug company
  • Novartis
  • Indication
  • CLL, sometimes in combination with chlorambucil, or with fludarabine + cyclophosphamide
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254




    Drug name (generic name)
  • Gazyva (obinutuzumab)
  • Drug company
  • Genentech
  • Indication
  • First-line treatment of CLL, in combination with Imbruvica
    First-line treatment of CLL, in combination with Venclexta
    Treatment of CLL, in combination with chlorambucil
  • Patient support services
  • Genentech BioOncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331






Chronic Myeloid Leukemia (CML)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services



    Drug name (generic name)
  • Iclusig (ponatinib)
  • Drug company
  • Takeda Oncology
  • Indication
  • Adults with chronic-, accelerated-, or blast-phase CML
    Adults with chronic-, accelerated-, or blast-phase CML with T315I mutation
  • Patient support services
  • Takeda Oncology 1Point
    844-817-6468

    Takeda Oncology Co-Pay Assistance Program
    844-817-6468




Hairy-Cell Leukemia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Lumoxiti (moxetumomab pasudotox-tdfk)
  • Drug company
  • AstraZeneca
  • Indication
  • Relapsed or refractory hairy-cell leukemia after systemic therapy
  • Patient support services
  • Access 360 Lumoxiti Patient Savings Program
    844-275-2360

Mast-Cell Leukemia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
Last modified: March 9, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country